INVO

INVO Bioscience

( )

vista's key points

INVO is commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective & affordable treatment for patients diagnosed with infertility.
INVOcell addresses key industry challenges regarding cost & capacity constraints: ability to help treat underserved patients as an alternative to traditional in vitro- fertilization (IVF)
~$15-$18 Billion global infertility industry growing ~8-10% annually.
Vast underserved global market ~95%+ of infertile individuals go untreated: significant unmet market opportunity.
U.S. commercialization agreement in January 2019 with Ferring Pharmaceuticals a multi-national firm and significant player in the global fertility drug market.
Distribution agreements in eight countries located within Africa, Asia, Europe and the Middle East.
Seeking to establish the initial 1-2 JV agreements, in Q1, for INVO-only clinics within the U.S. market.

company profile

vista's view

INVO Bioscience successfully conducted a public offering in November 2020, raising net proceeds of approximately $11.6 million at $3.20/share while uplisting the company onto the NASDAQ market. These moves strengthened their balance sheet & their position to execute on their commercialization efforts in the US and around the world. Analysts...

Page View Count : 97863